Single User License
INR 130140
Site License
INR 260280
Corporate User License
INR 390420

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Dilated Cardiomyopathy-Pipeline Review, H2 2015

Dilated Cardiomyopathy-Pipeline Review, H2 2015


  • Products Id :- GMDHC7032IDB
  • |
  • Pages: 55
  • |
  • August 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Dilated Cardiomyopathy-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Dilated Cardiomyopathy-Pipeline Review, H2 2015', provides an overview of the Dilated Cardiomyopathy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dilated Cardiomyopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dilated Cardiomyopathy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Dilated Cardiomyopathy

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Dilated Cardiomyopathy and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Dilated Cardiomyopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Dilated Cardiomyopathy pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Dilated Cardiomyopathy

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Dilated Cardiomyopathy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Dilated Cardiomyopathy Overview 6

Therapeutics Development 7

Pipeline Products for Dilated Cardiomyopathy-Overview 7

Pipeline Products for Dilated Cardiomyopathy-Comparative Analysis 8

Dilated Cardiomyopathy-Therapeutics under Development by Companies 9

Dilated Cardiomyopathy-Pipeline Products Glance 10

Clinical Stage Products 10

Early Stage Products 11

Unknown Stage Products 12

Dilated Cardiomyopathy-Products under Development by Companies 13

Dilated Cardiomyopathy-Companies Involved in Therapeutics Development 14

Array BioPharma Inc. 14

Hemostemix Ltd 15

Kasiak Research Private Limited 16

Sanofi 17

Vericel Corporation 18

Dilated Cardiomyopathy-Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Target 20

Assessment by Mechanism of Action 21

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Drug Profiles 26

ACP-01-Drug Profile 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

ARRY-797-Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

CAP-1002-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Drugs for Dilated Cardiomyopathy-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

ixmyelocel-T-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Refacell-DCM-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Small Molecule for Dilated Cardiomyopathy-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Dilated Cardiomyopathy-Recent Pipeline Updates 38

Dilated Cardiomyopathy-Dormant Projects 47

Dilated Cardiomyopathy-Product Development Milestones 48

Featured News & Press Releases 48

Jan 29, 2015: Vericel Completes Patient Enrollment in Phase 2b ixCELL-DCM Clinical Study of Ixmyelocel-T 48

Dec 19, 2013: Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia 48

Dec 17, 2013: Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack 48

Apr 19, 2013: Aastrom Biosciences Announces First Patients Treated In IxCELL-DCM Clinical Study Of Ixmyelocel-T 49

Jun 06, 2012: Aastrom Presents Preclinical Data Of Ixmyelocel-T At 18th Annual International Society For Cellular Therapy Meeting 50

May 10, 2012: Treatment With Ixmyelocel-T Shows Improvement In Outcome Of Heart Failure Patients 50

May 07, 2012: Aastrom To Present Phase IIa Trial Results Of Ixmyelocel-T In Dilated Cardiomyopathy Patients At SCAI Scientific Sessions 51

Oct 03, 2011: Aastrom Receives European Composition-Of-Matter Patent For Ixmyelocel-T 51

Sep 19, 2011: Aastrom Announces Positive 12-Month Safety And Efficacy Data From IMPACT-DCM Phase II Clinical Trial For Ixmyelocel-T In Treatment Of Dilated Cardiomyopathy 52

Sep 14, 2011: Aastrom To Present 12-Month Data From IMPACT-DCM Phase II Clinical Trial For Ixmyelocel-T In Treatment Of Dilated Cardiomyopathy 53

Appendix 54

Methodology 54

Coverage 54

Secondary Research 54

Primary Research 54

Expert Panel Validation 54

Contact Us 54

Disclaimer 55

List of Tables

Number of Products under Development for Dilated Cardiomyopathy, H2 2015 7

Number of Products under Development for Dilated Cardiomyopathy-Comparative Analysis, H2 2015 8

Number of Products under Development by Companies, H2 2015 9

Comparative Analysis by Clinical Stage Development, H2 2015 10

Comparative Analysis by Early Stage Development, H2 2015 11

Comparative Analysis by Unknown Stage Development, H2 2015 12

Products under Development by Companies, H2 2015 13

Dilated Cardiomyopathy-Pipeline by Array BioPharma Inc., H2 2015 14

Dilated Cardiomyopathy-Pipeline by Hemostemix Ltd, H2 2015 15

Dilated Cardiomyopathy-Pipeline by Kasiak Research Private Limited, H2 2015 16

Dilated Cardiomyopathy-Pipeline by Sanofi, H2 2015 17

Dilated Cardiomyopathy-Pipeline by Vericel Corporation, H2 2015 18

Assessment by Monotherapy Products, H2 2015 19

Number of Products by Stage and Target, H2 2015 20

Number of Products by Stage and Mechanism of Action, H2 2015 21

Number of Products by Stage and Route of Administration, H2 2015 23

Number of Products by Stage and Molecule Type, H2 2015 25

Dilated Cardiomyopathy Therapeutics-Recent Pipeline Updates, H2 2015 38

Dilated Cardiomyopathy-Dormant Projects, H2 2015 47

List of Figures

Number of Products under Development for Dilated Cardiomyopathy, H2 2015 7

Number of Products under Development for Dilated Cardiomyopathy-Comparative Analysis, H2 2015 8

Number of Products under Development by Companies, H2 2015 9

Comparative Analysis by Clinical Stage Development, H2 2015 10

Comparative Analysis by Early Stage Products, H2 2015 11

Assessment by Monotherapy Products, H2 2015 19

Number of Products by Top 10 Routes of Administration, H2 2015 22

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 22

Number of Products by Top 10 Molecule Types, H2 2015 24

Number of Products by Stage and Top 10 Molecule Types, H2 2015 24

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Array BioPharma Inc.

Hemostemix Ltd

Kasiak Research Private Limited

Sanofi

Vericel Corporation

Dilated Cardiomyopathy Therapeutic Products under Development, Key Players in Dilated Cardiomyopathy Therapeutics, Dilated Cardiomyopathy Pipeline Overview, Dilated Cardiomyopathy Pipeline, Dilated Cardiomyopathy Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com